Timbercreek Financial (TF) Price Target Cut to C$9.00 by Analysts at TD Securities

Share on StockTwits

Timbercreek Financial (TSE:TF) had its price target trimmed by TD Securities from C$9.50 to C$9.00 in a research report sent to investors on Thursday. The brokerage currently has a hold rating on the stock.

Separately, Fundamental Research set a C$10.34 price target on Timbercreek Financial and gave the company a buy rating in a research note on Thursday, November 22nd. Two equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Timbercreek Financial presently has a consensus rating of Buy and an average target price of C$9.78.

Timbercreek Financial stock opened at C$9.21 on Thursday. The company has a debt-to-equity ratio of 165.76, a quick ratio of 154.43 and a current ratio of 154.70. The company has a market capitalization of $745.48 million and a PE ratio of 14.10. Timbercreek Financial has a 12 month low of C$8.50 and a 12 month high of C$9.54.

About Timbercreek Financial

Timbercreek Financial Corporation, a mortgage investment company, provides shorter-duration structured financing solutions to commercial real estate investors in Canada. It focuses on lending against income-producing commercial real estate properties, such as multi-residential, office, and retail buildings located in urban markets.

Recommended Story: 52-Week High/Low

Receive News & Ratings for Timbercreek Financial Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Timbercreek Financial and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Magal Security Systems  Set to Announce Earnings on Wednesday
Magal Security Systems Set to Announce Earnings on Wednesday
BIOLINERX LTD/S  to Release Quarterly Earnings on Thursday
BIOLINERX LTD/S to Release Quarterly Earnings on Thursday
Uniti Group  Given New $8.00 Price Target at Deutsche Bank
Uniti Group Given New $8.00 Price Target at Deutsche Bank
Vertex Pharmaceuticals  Downgraded by BidaskClub to Hold
Vertex Pharmaceuticals Downgraded by BidaskClub to Hold
Zacks Investment Research Upgrades Ionis Pharmaceuticals  to “Buy”
Zacks Investment Research Upgrades Ionis Pharmaceuticals to “Buy”
BidaskClub Downgrades DENTSPLY SIRONA  to Hold
BidaskClub Downgrades DENTSPLY SIRONA to Hold


© 2006-2019 Ticker Report